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Abstract 
Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic 
droplet vaporization has introduced the possibility of expanding the diagnostic and thera-
peutic capability of ultrasound contrast agents to beyond the vascular space. Our laboratories 
have developed phase-change nanoparticles (PCNs) from the highly volatile PFCs de-
cafluorobutane (DFB, bp =-2 °C) and octafluoropropane (OFP, bp =-37 °C ) for acoustic 
droplet vaporization. Studies with commonly used clinical ultrasound scanners have 
demonstrated the ability to vaporize PCN emulsions with frequencies and mechanical indices 
that may significantly decrease tissue bioeffects. In addition, these contrast agents can be 
formulated to be stable at physiological temperatures and the perfluorocarbons can be mixed 
to modulate the balance between sensitivity to ultrasound and general stability. We herein 
discuss our recent efforts to develop finely-tuned diagnostic/molecular imaging agents for 
tissue interrogation. We discuss studies currently under investigation as well as potential 
diagnostic and therapeutic paradigms that may emerge as a result of formulating PCNs with 
low boiling point PFCs. 
Key words: Phase-change nanoparticles, extravascular imaging, ultrasound, perfluorocarbon, 
Acoustic droplet vaporization, diagnostic, therapeutic. 
Introduction 
Since their first use in ultrasonography by 
Gramiak and Shah over 40 years ago, the utility of 
microbubble-based contrast agents (MCA) in the 
clinical and research arenas has spanned both diag-
nostic and therapeutic applications [1-8]. Today ul-
trasound remains a highly desirable methodology for 
diagnostic imaging primarily due to its portability, 
and offers advantages over other imaging modalities 
because of its real-time, non-ionizing, high frame-rate 
imaging. Furthermore, ultrasound remains a low-cost 
modality that continues to decrease in system price 
with advances in manufacturing technology [9]. 
While advantageous in many respects, ultrasound 








the ability to use contrast agents for interrogation of 
the interstitial space and the physiologic processes 
occurring there. In PET/SPECT/MRI, diagnosing 
complex extravascular diseases can be approached 
with radionuclides or paramagnetic contrast agents 
[10]. 
In ultrasound imaging, there is great interest in 
designing contrast agents that can investigate sites of 
inflammation and solid tumors that result in highly 
permeable vascular networks [11-13]. However, ul-
trasound contrast agents currently approved for clin-
ical applications are produced in sizes that inherently 
restrict the particles to flow only through the vascular 
networks. Formulations of MCAs are typically de-
signed to balance a number of trade-offs involved 
with in vivo contrast imaging. First, because MCAs are 
typically administered through intravenous injection, 
they must be able to freely traverse capillary beds, 
and therefore must be similar to, or smaller than, the 
size of red blood cells (approximately 8 µm in diame-
ter) [14]. Second, reflected energy that results in im-
aging contrast is a function of both the scattering cross 
section (larger diameters resulting in greater contrast) 
and the microbubble’s natural resonance [15, 16]. 
Most studies have found that microbubbles in the 
several-micron diameter range produce a strong con-
trast signal at clinically relevant imaging frequencies, 
however, this size distribution also precludes MCAs 
from diffusing through ‘leaky’ tumor vasculature [17]. 
Researchers have attempted to overcome these 
limitations by designing nanoparticles still capable of 
some degree of echogenicity, such as gas-filled 
nanobubbles and perfluorocarbon (PFC) nanodroplets 
on the order of 100-500 nm – conceivably small 
enough to extravasate into permeable tumor types 
[18-24]. Nanoemulsions have been used in the past as 
drug delivery agents in conjunction with ultra-
sound-mediated localized delivery via radiation 
force/acoustic streaming [25]. The fact that these par-
ticles are often encapsulated in lipid shells may serve 
additional benefits – as outlined by Hendrickson and 
Lyon – in that soft colloids may have the ability to 
“squeeze” through pores due to additional elasticity 
[26]. Thus, it is possible that soft-shelled, lipid-coated, 
liquid-core perfluorocarbon nanoparticles may be 
able to extravasate through pores of significantly 
smaller size than their diameter would dictate. How-
ever, sub-micron bubbles produce substantially less 
image contrast than those in the micron size range for 
the same concentration and acoustic parameters. 
PFC droplets made from low boiling point 
compounds represent a unique approach in that they 
may be acoustically triggered to vaporize (typically 
termed acoustic droplet vaporization or ADV) to form 
bubbles much larger than the original droplet size – 
combining small initial particle size with high echo-
genicity. ADV has been proposed for a number of 
applications at both the microscale and nanoscale, 
such as selective vessel occlusion and various other 
forms of therapy and drug/gene delivery [27-29]. 
Much of the intellectual groundwork for na-
noscale ADV particles was formed in two early pa-
tents and more recent publications from several re-
searchers [30-35]. Expanding on ideas posited in the 
patent literature, researchers proposed the concept of 
a nanoemulsion small enough to accumulate at an 
interstitial target site and capable of being converted 
to the gaseous state through the application of ultra-
sonic energy and used to aid in therapeutic dose de-
livery. While in the liquid phase, these perfluorocar-
bon nanoparticles can be generated in the low 100s of 
nanometers, and can expand once activated to form 
gas-filled microbubbles on the order of 3-10 times 
larger in diameter depending upon whether they are 
in an air-saturated or degassed environment [31, 36, 
37]. 
Most previous studies of nanoscale ADV parti-
cles have relied upon the use of PFC compounds with 
boiling points above room temperature so as to 
maintain stability [31]. The lowest boiling perfluoro-
carbon core used until recently has been dode-
cafluoropentane (DDFP, bp = 29° C) while other larg-
er perfluorinated molecules such as perfluorohexane 
(bp = 57° C) have been used as well. For many appli-
cations, these compounds appear to be sufficiently 
susceptible to ultrasound to be activated at feasible 
acoustic parameters. However, as particle size moves 
towards the low 100s of nanometers, the amount of 
acoustic energy needed increases significantly as a 
result of additional Laplace pressure on the droplet 
core – effectively increasing the boiling point and 
acoustic energy needed to cause phase transition [32, 
36]. This increase in activation energy makes ap-
proaching diagnostic and molecular imaging applica-
tions with nanoscale ADV agents especially difficult. 
Recent reports have suggested that this effect is so 
great for some formulations that recently vaporized 
bubbles may even re-condense to the liquid state in 
the absence of ultrasound or cannot be vaporized with 
the full acoustic power of the ultrasound transducer 
[38, 39]. 
One possibility for increasing the sensitivity of 
these types of agents is to develop them from com-
pounds more volatile than previously considered. By 
the same effect that allows DDFP to form nano- and 
microscale droplets that remain in the liquid state at 
temperatures much higher than their normal boiling 
point, droplets might be formed from perfluorocar-




bons such as DFB and OFP [40]. Figure 1 shows the 
effect of perfluorocarbon boiling point as a function of 
pressure [32, 36]. Note that the boiling points of per-
fluorohexane and DDFP exceed their standard boiling 
points found under standard temperature and pres-
sure quite substantially. While the curves suggest that 
microscale droplet of DFB and OFP would likely be 
highly unstable, droplets formed from these highly 
volatile fluorocarbons at the nanoscale may be stabi-
lized and vaporized with significantly less energy 
than their counterparts formulated from less volatile 
perfluorocarbons.  
Using this as a rationale for development, we set 
out to demonstrate stabilization of highly volatile 
perfluorocarbons as a new class of dynamic, activata-
ble biomaterials. With the assumption that lower 
boiling perfluorocarbons are necessary to maintain 
reasonable ultrasound output requirements for va-
porization of 100 – 200 nm nanoparticles, we hypoth-
esized that low boiling DFB (and later octafluoropro-
pane) nanoparticles could be formulated and main-
tain their stability at physiologic temperatures and 
that they would be subject to vaporization at lower 
ultrasound outputs. A pictorial diagram of the design 
is shown in Figure 2. 
 
 
Figure 1. Vaporization temperature predictions for perfluorocarbon particles as a function of droplet diameters. Reprinted with per-




Figure 2. Pictorial diagram for making phase-change nanoparticles of submicron size distribution using pressurization and slow cooling to 
condense the gas inside the microbubbles. Reprinted with permission from Langmuir. Copyright 2011 American Chemical Society. 







Initially, the approach to form stable DFB nano-
particles was to condense the PFC compound at re-
duced temperatures and subsequently mix the re-
sulting liquid aliquot with a lipid cocktail consisting 




PEG-2000). The samples could then be extruded in a 
cold room (-20° C) using a hand-held extruder and 
passing through porous membranes. Our initial re-
sults demonstrated that indeed liquid DFB could be 
stabilized into lipid-coated particles that remained 
stable at body temperature, and that vaporization 
could occur at acoustic parameters less likely to in-
duce cavitation-based bioeffects than alternative 
compounds. Figure 3 demonstrates the vaporization 
pressure of the largest, optically resolvable DFB 
droplets present in each sample as a function of par-
ticle size when exposed to 5 MHz ultrasound in a 
degassed water bath. Using these large particles al-
lowed for simple measurement of individual droplet 
vaporization thresholds, and made comparisons be-
tween compounds facile. As was expected, the me-
chanical index (MI: defined as the peak negative 
pressure in MPa divided by the square root of the 
center frequency in MHz) decreased significantly for 
droplets composed of DFB compared to dode-
cafluoropentane and perfluoro(2-methyl-3- 
pentanone) [bp 49.2 ºC] – highlighting the expected 
relationship between reduced initial boiling point and 
a lower acoustic vaporization threshold.  
However, despite their apparent stability and 
the fact that sensitivity to ultrasound was higher than 
other perfluorocarbons, the size of the DFB particles 
generated by extrusion were primarily in the micron 
range regardless of membrane pore size, and the ex-
trusion method appeared somewhat unreliable with 
respect to making predominantly smaller particles. 
This may be due to secondary effects such as aggre-
gation, coalescence, or Ostwald Ripening. Alterna-
tively, the malleability of the liquid DFB along with 
the very low surface tension could deform through 
the filter pores, forming a droplet much larger than 
the filter pore diameter.  
Through these initial studies, the need for uni-
form-sized nanoparticles that were also resistant to 
aggregation, coalescence and/or Ostwald ripening 
became apparent [41]. One possible method that was 
entertained was based upon microbubble sizing 
studies by Borden and coworkers who found that 
upon administration of pressure at approximately 100 
kPa of ambient pressure for nine cycles, the mi-
crobubble size would “jump” to a smaller size distri-
bution [42]. Based upon this knowledge, we hypothe-
sized that if pressure alone would promote a smaller 
size distribution, then perhaps a combination of in-
creased pressure and reduced ambient temperature 
could cause DFB microbubbles to collapse and/or 




Figure 3. Ultrasound vaporization thresholds (mechanical index) of individual particles as a function of initial particle diameter when 
exposed to 5 MHz ultrasound (10 cycles). Decafluorobutane droplets require significantly less energy than droplets composed of higher 
boiling point compounds. Reprinted from Ultrasound in Medicine & Biology. Vol. 37 (9). Sheeran PS, Wong VP, Luois S et al. De-




cafluorobutane as a Phase-Change Contrast Agent for Low-Energy Extravascular Ultrasonic Imaging. pgs. 1518-1530, Copyright 2011, 
with permission from Elsevier. *note: rarefactional pressure (in MPa) can be calculated from the mechanical index with 𝑃𝑛𝑒𝑔 = 𝑀𝐼 × √5 
This method of ‘microbubble condensation’ uti-
lizing ambient pressures on the order of 300-500 kPa 
and cooling below 0 °C, successfully generated DFB 
PCNs with a smaller distribution as determined by 
particle sizing methodology. As can be seen in Figure 
4, the size distribution after applying pressure and 
reduced temperature at three lipid concentrations 
yielded a particle distribution on the order of 200 nm 
to 300 nm in diameter. More recent studies have 
shown that similar results can be achieved with much 
lower ambient pressures – using cooling as the pri-




Figure 4. Submicron particle sizing of nanodroplets produced by 
the microbubble condensation method. Peak sizes of 200 - 300 nm 
resulted, which appeared to be independent of lipid concentration. 
Mean droplet size for each curve in order of increasing lipid 
concentration was 229 ± 120, 345 ± 97, and 325 ± 268 nm, re-
spectively. Mode droplet size was 220, 295, and 255 nm, respec-
tively. Reprinted with permission from Langmuir. Copyright 2011 
American Chemical Society. 
 
 
Subsequent vaporization of the PCNs by acous-
tic energy yielded a majority of microbubbles in the 1 
– 2 micron range (Figure 5). These results show the 
distribution of vaporized microbubbles as a function 
of two different mechanical indices (MI = 1.2 and 1.7, 
or 2.7 MPa and 3.8 MPa) at a 5 MHz center frequency. 
As the MI is increased, the resultant distribution 
skews towards smaller diameters, likely due to in-
creased efficiency in vaporization of the small drop-
lets. It is also noted that this distribution was achieved 
by increasing the total lipid concentration to 3 mg/mL 
of total lipid in the formulation, possibly an indication 
of more stabilized PCNs in the milieu, though most of 
our ongoing studies use lipid concentrations near 1 
mg/mL. In addition, the microbubble sizing profiles 
were very similar to the original microbubble pre-
cursor size distributions, which suggests not only that 
the precursors were efficiently converted to 
nanodroplets and could be converted back to the 
gaseous state, but that this technique allows the pos-
sibility of highly tailoring the resulting 
‘post-vaporization’ microbubble distributions beyond 




Figure 5. Microbubble diameter post vaporization as a function 
of acoustic pressure at 5 MHz frequency and lipid concentration of 
3 mg/mL. As pressure increases, the distribution skews towards 
smaller resultant microbubble diameters. Reprinted with per-
mission from Langmuir. Copyright 2011 American Chemical 
Society. *note: rarefactional pressure (in MPa) can be calculated from 
the mechanical index with 𝑃𝑛𝑒𝑔 = 𝑀𝐼 × √5. 
 
 
To our knowledge, these studies represent the 
first proofs-of-principle of the potential for formulat-
ing PCNs from highly volatile perfluorocarbons for 
ultrasound-mediated vaporization in vivo. To date, we 
have observed that, while some degree of spontane-
ous vaporization is present (thermal instability), a 
substantial number of droplets remain stable while 
incubated in cell culture for periods longer than 4 
hours under physiologic conditions and can be va-
porized with clinical diagnostic acoustic parameters 
afterward (unpublished data). More recently, this 
methodology was expanded to the use of an even 
more volatile perfluorocarbon – octafluoropropane 
(bp = -36.7 °C) at the expense of thermal stability. As 
was expected, the ultrasound vaporization threshold 
for the OFP nanoparticles was significantly lower 
than DFB (see Figure 6) – further confirming that a 
more volatile perfluorocarbon yielded a more easily 




vaporizable particle albeit at decreased stability at 
physiologic temperatures, and confirming the signif-




Figure 6. Rarefactional pressure required to vaporize droplets of 
based on initial diameter, and as a function of PFC composition 
(decafluorobutane, octafluoropropane and a 50:50 mixture of the 
two gasses). Measurements taken at room temperature (22°C) 
using an 8 MHz ultrasound transducer with a 2-cycle pulse length. 
Note the intermediate pressure required for vaporization of the 
mixture. Reprinted from Biomaterials. Vol. 33. Sheeran PS, Luois S, 
Mullin LB et al. Design of ultrasonically-activatable nanoparticles 
using low boiling point perfluorocarbons. pgs. 3262-68, Copyright 
2011, with permission from Elsevier. 
 
 
In addition, it is worth noting that, although the 
technique of particle generation via decreased tem-
perature and increased ambient pressure is advanta-
geous over extrusion-based techniques for use with 
lower-boiling perfluorocarbons, the methodology 
requires refinement. For example, we observe that 
upon condensation, the resulting emulsions can often 
contain droplets larger than 2-3 µm in diameter. These 
represent an insignificant part of the overall distribu-
tion, but are likely to have high significance in vivo. 
Large outliers in ADV emulsions vaporize much more 
easily than the smaller particles present, provide 
much higher contrast (thereby skewing data), and 
perhaps more importantly – can cause unwanted 
embolization or damage if too large. In these emul-
sions, the particles may result from; 1) a small number 
of very large bubbles present in the precursor bubbles; 
2) larger gas pockets sequestered within the mi-
crobubble matrix; or; 3) could possibly be a result of 
pressure or temperature inducing Ostwald ripening 
or aggregation and coalescence of the microbubbles or 
resultant nanoparticles. However, this might be recti-
fied by changing the rate of pressurization so as to 
retard any coalescence effects. In addition, elimination 
of large bubbles may be rectified by utilizing 
flow-filtering techniques upon initial microbubble 
distributions to achieve a more uniform size prior to 
condensation [16, 44]. Current efforts are focused 
upon understanding this phenomenon and refining 
the resulting distributions. Nonetheless, this method 
of utilizing pre-formed microbubbles is advantageous 
over membrane extrusion where it may not be feasible 
to extrude at temperatures below the boiling point of 
the perfluorocarbon (i.e. octafluoropropane where 
extrusion would have to occur at or below -37 ºC) – 
well below the freezing point of the lipid colloidal 
solution.  
An additional caveat to this discovery was the 
fact that a variety of different lipid combinations were 
used as stabilizing shells for the PCNs. In fact, virtu-
ally all combinations of lipids used to date have been 
successfully utilized as stabilizing shells. The impli-
cations of this flexibility in shell composition is nota-
ble, as we have used as much as 30 mole% cationic 
lipids (i.e. 1,2-dipalmitoyl-3-trimethylammonium 
propane (chloride salt; 16:0 TAP)) - which is useful for 
electrostatic complexing of plasmids to the nanopar-
ticle surface, thereby making them suitable for gene 
delivery. In addition, the lipid shell can be comple-
mented with other components so as to make the 
shells more rigid (or malleable as the case may be) 
thereby altering the stability and vaporizability of the 
PCNs. 
Post-Vaporization Bubble Growth Sec-
ondary to Gas Diffusion  
As was described previously in ADV experi-
ments with DDFP microdroplets by Kripfgans et al., 
microbubbles formed by vaporization continue to 
expand with time beyond ideal gas law predictions 
due to the influx of dissolved gas in the milieu, and 
has been confirmed by others with nanoparticle for-
mulations [37, 45]. This was also observed in our 
studies of ADV-induced DFB microbubbles. Using 
both degassed and undegassed aqueous milieu, it was 
demonstrated that, upon acoustic vaporization, the 
resultant diameter of the newly formed microbubbles 
in the undegassed solution was significantly larger 
than those in the degassed solution. In fact, in the 
degassed milieu, the resultant diameter closely ap-
proximated that of those predicted using simple ideal 
gas law estimations for liquid–to-gas conversions 
(approx. 5 – 6 fold increase in diameter). This can be 
seen in Figure 7. Note, that this has also been demon-
strated previously by Lundgren et al. for dode-




cafluoropentane microbubbles that were intended for 
use as a blood substitute [46, 47] as well as a nitrogen 
“scrubber” for potentially treating underwater nitro-
gen toxicity [48]. More recently, Reznik et al. (2012) 
demonstrated that depending on shell composition, 
vaporized PFC droplets may expand to between 
10-50x their initial diameter over the course of 15 




Figure 7. Corresponding Microbubble diameters (y-axis) after 
ultrasound-mediated vaporization of PCNs. Reprinted from Ul-
trasound in Medicine & Biology. Vol. 37 (9). Sheeran PS, Wong VP, 
Luois S et al. Decafluorobutane as a Phase-Change Contrast Agent 
for Low-Energy Extravascular Ultrasonic Imaging. pgs. 1518-1530, 
Copyright 2011, with permission from Elsevier. 
 
This post-vaporization expansion is likely to be 
an important component in vivo, and requires further 
study. In some aspects, this may be beneficial – as a 
larger bubble will result in increased ultrasound 
backscatter and higher contrast in imaging (or, alter-
natively, allows for use of smaller droplets) – alt-
hough it may result in non-ideal bubble sizes for ap-
plications involving acoustic radiation force manipu-
lation of the resulting bubbles (dependent on ideal 
resonance diameters) [50]. 
Modulation of Ultrasound Vaporization 
Energy by Modifying Perfluorocarbon 
ratios 
Previous work by Kawabata and coworkers ex-
plored the possibility of modulating ultrasound out-
put requirements for initiating droplet vaporization 
[34]. They approached this goal by the mixing of two 
liquid perfluorocarbons to determine if the combina-
tion would modulate the boiling point similar to an 
azeotrope. This same concept can be extended to 
modulate the stability and ultrasound sensitivity of 
droplets formed from highly volatile gaseous per-
fluorocarbons. Thus, our approach mirrored that of 
Kawabata et al. with the exception that it used mix-
tures of DFB and OFP while in the gaseous state prior 
to condensation. A 1:1 (v:v) mixture of DFB and OFP 




methoxy(polyethyleneglycol)- 2000 (DSPE-PEG2000) 
in a 9:1 M ratio and a total lipid concentration of 1.0 
mg/mL [51]. Results indicated that the mixture of two 
volatile perfluorocarbon gases condensed together 
would result in a mixed liquid droplet with stability 
and sensitivity to ultrasound between droplets com-
posed of each of the ‘parent’ compounds. Figure 6 also 
demonstrates the change in acoustic output as a func-
tion of either pure condensed perfluorocarbons or a 
1:1 mixture. As can be seen, the 1:1 mixture modu-
lated the vaporization rarefractional pressure to an 
intermediate level between the two pure gas PCNs 
containing OFP and DFB. This exciting result demon-
strates that the vaporization parameters can be altered 
as a function of the gas mixture and potentially fine-
ly-tuned for specific applications.  
Indeed, as was also believed, the stability of the 
nanoparticle could be modulated as well. Using an 
Accusizer 780 optical particle sizing system (Particle 
Sizing Systems, Santa Barbara, CA), we were able to 
size the nanoparticles as a function of time at two 
temperatures, 22 ºC and 37 ºC. The sizing of the na-
noparticles was constrained by the limits of meas-
urement methodology (≥ 500 nm). However, as an 
estimation of stability between different formulations, 
this approach was justified since smaller nanoparti-
cles subject to higher Laplace pressures will exhibit 
generally greater stability than the portion of the 
samples greater than 500 nm. Results indicated that 
over the period of 60 minutes, DFB nanoparticles ex-
hibited high stability at both temperatures with only 
small changes in distribution or particle count. Mix-
tures of 1:1 DFB and OFP exhibited a 17% decrease in 
mean concentration at 22 ºC and 45% at 37 ºC. Nano-
particles made entirely of OFP exhibited the least sta-
bility with an 82% drop in concentration over 60 
minutes at both 22 ºC and 37 ºC (Figure 8). Studies are 
ongoing to determine whether this balance of stability 
and ultrasound sensitivity can be altered more fa-
vorably by mixing highly volatile PFCs (OFP, DFB) 
with PFCs that are in the liquid state at room temper-
ature (DDFP, PFH). It may be that mixing a highly 
volatile PFC such as OFP with a higher molecular 
weight compound will maximize stability while re-
taining much of the desired sensitivity to ultrasound. 




Interestingly, the above results demonstrate an 
important phenomenon worth discussion at this time; 
that being that combination of perfluorocarbon mix-
tures based upon their volatility allows one to modu-
late both the stability and the vaporization thresholds 
of the PCNs. This discovery can have important im-
plications for both nanoparticle delivery and potential 
therapeutic paradigms. First, modulating the stability 
of PCNs through these methods can potentially allow 
for the design of PCNs with controlled circulating 
half-lives based upon the specific application the 
PCNs for which they are intended. This is extremely 
desirable with regard to extravascular imaging and 
therapy where longer circulating times will be re-
quired for accumulation in the interstitial space. 
However, too much stability could also impair the 
efficiency of the particle vaporization. In other words, 
the nanoparticles may be able to be designed opti-
mally for the competing aspects of delivery, imaging, 
and therapeutic manipulation. Second, if the vapori-
zation thresholds of these PCNs can be modulated, 
we may be able to apply only as much ultrasound as 
is required to image or elicit therapeutic effect, 
thereby avoiding potential bioeffects. Third, an addi-
tional advantage of being able to modulate these 
PCNs would be to allow for optimizing the emulsions 
for specific aspects of separation of different compo-
nents of ultrasound mediated delivery (i.e. radiation 
force and acoustic streaming), vaporization (i.e. con-
version from nanoparticle to microbubble for imag-
ing), and finally cavitation (inertial or stable cavitation 
of resultant microbubble) for the purposes of thera-
peutic manipulations (i.e. vascular occlusion, sono-
thrombolysis, and intracellular ablation). Experiments 
are continuing in our laboratories, as well as others, to 




Figure 8. Perfluorocarbon droplet distributions in vitro over a 1 h period: Pure DFB at a) 22 C and b) 37 C; DFB . OFP mixture at c) 22 
C and d) 37 C; and pure octafluoropropane at e) 22 C and f) 37 C. The distribution at each time point was scaled to the relative mean 
concentration (concentration-weighted) to simultaneously reflect changes in concentration over the time period. Reprinted from Bio-
materials. Vol. 33. Sheeran PS, Luois S, Mullin LB et al. Design of ultrasonically-activatable nanoparticles using low boiling point per-
fluorocarbons. pgs. 3262-3268, Copyright 2011, with permission from Elsevier. 






Since PCNs formed by microbubble condensa-
tion have lipid membranes stabilizing their surface, 
they are also amenable to decoration by targeting 
ligands on their membrane surface - the same strategy 
commonly applied to microbubble targeting schemes 
[52]. We demonstrated the ability to develop PCNs 
targeted to cellular receptors/biomarkers for the 
purposes of molecular imaging using a cyclic RGD 
peptide conjugated to a lipid-PEG component on the 
shell [53,54]. Utilizing human umbilical vein endothe-
lial cells (HUVECs) known to upregulate αvβ3 recep-
tors on the membrane surface, PCNs were incubated 
for 15 minutes with cells grown on acoustically 
transparent Thermanox® plates [55]. Samples were 
then exposed to ultrasound energy at 8 MHz (MI = 
1.1) delivered via a clinical ultrasound machine 
(Acuson Sequoia 512, 15L8 linear array transducer) to 
mediate vaporization, and imaged with the same 
machine at low acoustic energy (7 MHz, MI = 0.18) in 
both B-mode and contrast-specific CPS mode to 
measure the resulting increase in image contrast due 
to the PCNs. Results (see Figure 9) indicate a statisti-
cally significant increase (p = 0.02) in binding of tar-
geted droplets over control, sham-targeted droplets – 
registered as a six-fold improvement in mean ultra-
sound intensity after vaporization to microbubbles. 
Figure 10 shows a volumetric rendering of individual 
B-mode scans (greyscale) with contrast-specific signal 
overlays (greenscale). After the vaporization pulse, a 
region of high contrast is visible in the HUVEC cell 
layer due to adherent post-vaporization microbubbles 
on the surface of the cells, demonstrating that the 
vaporized bubbles remain attached to the HUVEC 
cellular membrane surface and do not float to the 
surface of the covering slide. This suggests that the 
newly formed microbubbles will likely retain their 
encapsulating shell to some degree, and that the tar-
geting ligands will maintain their adherence during 
PCN-to-microbubble conversion – enabling 
ADV-based molecular imaging. Thus, ADV-based 
molecular imaging may have significance for both 
vascular and extravascular applications due to the fact 
that, once bound to a receptor target, sufficient clear-
ance time to both the vascular and extravascular space 
can be afforded such that only the adherent particles 
will be seen after activation.  
Clinical/Translational Implications and 
Future Directions 
The use of PCNs may have widespread applica-
tion and could significantly change the breadth of 
targeted microbubble agents to include imaging or 
delivery to extravascular targets as opposed to being 
limited to intravascular flow or targeting endothelial 
biomarkers. Below are descriptions of just a few po-
tential new areas of research that may be pursued 
with these new PCNs based on highly volatile per-
fluorocarbons.  
Tumor Cell Ablation, a 
non-pharmacologic approach 
Extravascular delivery of volatile PCNs in the 
interstitial space can potentially be accompanied by 
vaporization and/or cavitation of resultant mi-
crobubbles to aid in the ablation of regions of pa-
thology (i.e. tumor cells). Currently, there are reports 
of PCNs acting as nucleation sites for HIFU tumor 
ablation [35]. In addition, Kang and Yeh have re-
ported the successful delivery of perfluoropentane 
PCNs to the intracellular compartment of macro-
phages (referred to as drug-loaded macrophages) 
followed by ADV and subsequent inertial cavitation. 
They propose the use of macrophages as transporters 
of the PCNs to the extravascular space [56]. Low 
boiling point PCNs may have the potential to activate 
these droplets more efficiently and enhance the effect 
even more with less inherent peripheral bioeffects 






Figure 9. Mean scattering intensity as a function of PCN binding 
to HUVEC cells. Note the significant increase in scattering inten-
sity with targeted PCNs vs. untargeted PCNs, demonstrating that 
the cyclic RGD ligand targets αvβ3 expression in the HUVEC cells, 
and that the PCNs are capable of providing quantitative infor-
mation on molecular expression at the cellular level. © 2012 IEEE. 
Reprinted, with permission from P.S. Sheeran et al., "Ultrasound 
molecular imaging with customizable nanoscale phase-change 
contrast agents: an in-vitro feasibility study", 2012 IEEE International 
Ultrasonics Symposium (IUS) Proceedings, In Press, 2012. 






Figure 10. Overlays of contrast-specific CPS (green) and B-mode (grey) ultrasound scans of HUVEC cells incubated with targeted PCNs: 
Prior to activation, no contrast-specific echogenicity is detected, suggesting no microbubbles have formed. After exposure to a mechanical 
index of 1.1 at 8 MHz, targeted droplets vaporize to the highly-echogenic microbubble state and remain in the plane of the HUVEC cells. 
*note: rarefactional pressure (in MPa) can be calculated from the mechanical index with 𝑃𝑛𝑒𝑔 = 𝑀𝐼 × √8. © 2012 IEEE. Reprinted, with per-
mission from P.S. Sheeran et al., "Ultrasound molecular imaging with customizable nanoscale phase-change contrast agents: an in-vitro 
feasibility study", 2012 IEEE International Ultrasonics Symposium (IUS) Proceedings, In Press, 2012. 
 
Alternatively, nanoparticle delivery to the in-
tracellular space followed by vaporization may offer 
unique opportunities for tissue and tumor cell abla-
tion provided that the particles can be situated near 
regions where sub-cellular damage can induce an 
apoptotic or lethal event. Thus, a possible area of in-
terest would be to deliver PCNs to cellular surfaces 
followed by intracellular uptake and targeting to 
subcellular organelles (i.e. via nuclear localization 
sequences for example). As an example, therapeutics 
can be conjugated to nuclear localization sequences 
such that upon intracellular delivery (endocytosis or 
membrane diffusion), a migration to the nucleus can 
be achievable for enhanced tumor destruction [57, 58]. 
Similar methods may be feasible for intracellular de-
livery of PCNs followed by imaging and/or ablation. 
This may provide the opportunity for a theranostic 
approach whereby microbubbles resulting from 
droplet vaporization may be utilized for imaging tu-
mor cells selectively from the intracellular milieu as 
well as following tumor regression if cells can be ab-
lated by either ;1) radiation force secondary to particle 
vaporization, or; 2) cavitation of the microbubble. It is 
also possible that cellular destruction could be 
achieved by the combination of the two. Thus, by 
modulating the ultrasound output, one may be able to 
generate a sufficient “shockwave” to compromise the 
target, thereby eliciting sufficient damage to induce 




apoptosis. In addition, since the ablation could poten-
tially occur from the intracellular compartment of the 
tumor cell, this could lead to selective tumor cell ab-
lation with a minimum of bioeffects to surrounding 
cells. It would be expected that the shockwave would 
dissipate quickly over space and primarily effect the 
targeted cell. This hypothesis is supported by data, 
which suggests bubble-induced cell membrane effects 
are greatest within one bubble diameter of the cell, 
and fall off rapidly at greater distances [59]. 
Sonothrombolysis 
Despite the potential utility for extravascular 
application, PCNs may also be utilized for intravas-
cular delivery for imaging and therapy of conditions 
such as vascular thrombi. Currently, microbubbles 
have been explored for this purpose [60-62], however, 
an increase in circulation time plus the benefit of ac-
tivating at a specific site may make PCNs a viable 
alternative to microbubbles for the purposes of Son-
othrombolysis. Because their size is in the 100s of nm 
range, they may offer advantages over microbubbles 
for permeating into the thrombus matrix, at which 
point they may be activated and even cavitated for 
lysing the clot. In addition, by virtue of their size and 
surface pegylation, PCNs may be less subject to 
elimination than microbubbles. As such, they may 
offer increased utility as a therapeutic agent for the 
purposes of acute clot dispersion. Finally, due to the 
use of lower ultrasound output for vaporization, they 
may potentially offer significant improvements over 
current sonothrombolytic therapies especially in 
terms of decreased adverse effects as the effect would 
be elicited primarily through the “shockwave” im-
parted from the vaporization of the droplet to the 
microbubble as opposed to the subsequent mi-
crobubble eliciting an effect through inertial cavita-
tion. Current evidence indicates that this would be the 
case as the rationale for using vaporization with 
low-boiling perfluorocarbons is that the transition 
from droplet to microbubble requires less energy than 
microbubble cavitation.  
Gene and Drug Delivery 
The flexibility of the formulation method and the 
ability to enhance delivery to the interstitial space by 
the enhanced permeability and retention (EPR) effect 
opens opportunities for more efficient ultra-
sound-mediated gene therapy directed to specific 
tissues. Because droplets can be generated with cati-
onic shells, the opportunity for electrostatic decora-
tion of the nanoparticle shell with plasmids is indeed 
possible. Furthermore, the modification of the for-
mulation with mixtures of perfluorocarbons (both 
volatile and less volatile) provides the means to 
modulate the ultrasound requirements for ADV. This 
also implies that one could adjust vaporization po-
tential such that we may be able to delineate separate 
ultrasound requirements for imaging, radiation force 
and acoustic streaming, vaporization, and microbub-
ble cavitation - which should aid in more controlled 
delivery, activation, and microbubble cavitation to 
promote gene and drug delivery.  
Characterization of Enhanced Permeabil-
ity and Retention Effect 
The effects of leaky endothelial gap junctions 
and the resultant increased diffusion of small mole-
cule drugs have been addressed previously. However, 
this effect, despite a good deal of precedence, has been 
difficult to quantify. PCNs, by virtue of their ability to 
potentially extravasate, may conceivably be activated 
in the region of the tumor tissue space followed by 
vaporization and quantitating ultrasound backscatter 
from resultant microbubble formation. The quantita-
tion might then be used as an indication of the num-
ber of PCNs that have diffused into the tissue space. 
Thus, one may be able to quantify the level of extrav-
asation as a function of the passive diffusion of na-
noparticles of known size into the region of interest. 
This could be somewhat helpful with respect to de-
termining the ability of passive diffusion of nanopar-
ticle delivery agents in the region of angiogenesis [11, 
13]. Consequently, a general determination of the 
’treatability’ potential of a tumor via ADV agents 
could lead to optimization of dosage based upon tu-
mor burden and angiogenic vessel permeability. 
Lymphatic Imaging 
Previous studies have shown the ability to use 
microbubbles for sentinel node imaging as an indica-
tor of cancer spread and disease progression [63, 64]. 
Some effort has focused upon the use of microbubbles 
to image lymphatics in the in the stomach and in 
peritumoral regions of cancer [65, 66]. Thus, lym-
phatic imaging could be amenable to PCN studies as 
well, and may be aided by the small particle size 
compared to microbubble agents. 
Theranostics 
As described above, the localization and vapor-
ization of a PCN intracellularly offers the opportunity 
to create a therapeutic response and to be able to im-
age the particular cell simultaneously. Thus, it is pos-
sible that one could monitor the progress of therapy 
using localized, intracellularly deposited PCNs and 
using ultrasound imaging while at the same time, 




initiate therapy and follow regression of the disease.  
Imaging of Digestive Organs 
An area of interest that may be explored is the 
imaging of the digestive organs. Although trans-
abdominal ultrasound imaging of the alimentary tract 
is difficult secondary to luminal gas artifacts, endo-
scopic ultrasound overcomes this by imaging through 
water instilled in the lumen or by imaging through a 
water-filled balloon attached to the tip of the endo-
scope [67-70]. 
The esophagus is of particular interest, as it is 
easily accessible, can be filled with fluid and is the 
organ that houses a common cancer with an increas-
ing incidence [71]. Adenocarcinoma of the esophagus 
is a complication of Barrett’s esophagus, where the 
normal squamous epithelium is replaced by intestinal 
metaplasia in response to gastroesophageal reflux 
[72,73]. The progression from Barrett’s to esophageal 
cancer occurs through stages of low and high grade 
dysplasia, which are not visible to the naked eye. 
Currently, blind four quadrant biopsies are per-
formed at one to two cm intervals, which sample less 
than five percent of the Barrett’s mucosa and are thus 
open to sampling error [74]. This is particularly wor-
risome as the smallest areas of high grade dysplasia 
can be no more than a few mm in diameter). Ligands 
have now been identified that enable areas of high 
grade dysplasia and cancer to be imaged with fluo-
rescent antibodies [75,76]. Targeted attachment of 
PCNs via small ligands will enable the dysplastic and 
cancerous cells to be located, but additionally help to 
facilitate targeted destruction of such cells, without 
the pain and complications of non-selective therapy 
[77]. Furthermore, following targeted ablation, pa-
tients can be surveyed for evidence of remaining or 
recurrent dysplasia and retreated by a technique that 
will be highly selective and thus more effective and 
with few complications.  
A second application of such techniques would 
be in the bile and pancreatic ducts that are commonly 
accessed and cannulated during endoscopy. The at-
tachment of PCNs to targets such as Claudin-4 and 
mixed matrix-metaloperoxidase-7 that are expressed 
in dysplasia and cancer could enable neoplastic stric-
tures of bile and pancreatic ducts to be imaged and 
ablated [78, 79]. Similarly, such techniques can be 
used during surgery to assist the surgeon excise all 
microscopic cancer, which is currently not possible, 
for a substantial improvement in long-term survival 
[80]. 
Conclusion 
Phase-change nanoparticles may show promise 
as potential extravascular contrast agents if we are 
able to induce vaporization at acceptable ultrasound 
outputs so as to elicit the desired response without the 
undesirable bioeffects. As future work continues to 
mature, PCNs may show promise as vascular and 
enteral contrast agents as well. Work by others has 
demonstrated the utility and potential of perfluoro-
carbon liquid particles for imaging and therapeutic 
applications [81, 82]. The stabilization of highly vola-
tile perfluorocarbons may help to bridge the applica-
tions into the extravascular space. Indeed, further 
work is still necessary in this area however, it has the 
potential to expand the realm of ultrasound contrast 
agents to develop approaches to interstitial tissue 
imaging and therapy that is currently only available 
to other modalities. Furthermore, potential advances 
in nanoparticle delivery to regions of the intracellular 
space, enteral space, and lymphatics may offer the 
opportunity for additional theranostic paradigms to 
be developed. Finally, although much future work is 
needed, maturation of any of the above areas opens 
the door for highly translational projects to develop 
into clinical realities.  
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